068270.KS
Celltrion, Inc.
KSC · Healthcare · Biotechnology · KR
KRW 187,100.00
+0.43%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 4897.8B | 4162.5B | 3557.3B | 2176.4B | 2284.0B |
| Cost of Revenue | 1924.7B | 1766.3B | 1875.6B | 1165.5B | 1251.3B |
| Gross Profit | 2973.1B | 2396.2B | 1681.7B | 1010.9B | 1032.7B |
| Operating Expenses | |||||
| R&D Expense | 106.7B | 208.0B | 199.7B | 161.1B | 139.7B |
| SG&A Expense | 323.2B | 554.6B | 456.9B | 198.4B | 120.1B |
| General & Admin Expense | (145.0B) | 86.3B | 78.1B | 29.5B | 60.5B |
| Selling & Marketing Expense | 468.2B | 468.2B | 378.8B | 78.4B | 59.7B |
| Other Expenses | 997.5B | 469.1B | 533.1B | 131.4B | 125.6B |
| Total Operating Expenses | 1427.4B | 1231.7B | 1189.7B | 359.5B | 385.5B |
| Cost and Expenses | 3347.6B | 2994.0B | 3065.3B | 1525.0B | 1636.8B |
| Operating Income (EBIT) | 1545.7B | 1168.5B | 492.0B | 651.5B | 647.2B |
| Non-Operating | |||||
| Interest Income | 26.1B | 23.2B | 33.5B | 19.1B | 14.2B |
| Interest Expense | 93.9B | 75.5B | 75.6B | 9.7B | 7.5B |
| Net Interest Income | (67.8B) | (52.3B) | (42.0B) | 9.4B | 6.7B |
| Other Non-Op Income/Expense | 245.6B | (14.8B) | 84.1B | 19.6B | (21.0B) |
| Non-Operating Income (excl Interest) | (168.1B) | — | (159.7B) | (40.6B) | 20.6B |
| EBT (Pre-Tax Income) | 1795.8B | 1153.7B | 576.1B | 671.1B | 626.2B |
| Income Tax Expense | 214.8B | 122.2B | 157.2B | 131.4B | 94.8B |
| Bottom Line | |||||
| Net Income | 1576.7B | 1031.5B | 422.7B | 535.6B | 537.8B |
| Earnings from Cont. Ops | 1581.0B | 1031.5B | 418.9B | 539.7B | 531.3B |
| Earnings from Discont. Ops | — | — | — | — | 11.2B |
| Bottom Line Net Income | 1576.7B | 1031.5B | 422.7B | 535.6B | 537.8B |
| Per Share | |||||
| Basic EPS | ₩6,929 | ₩4,466 | ₩1,969 | ₩3,442 | ₩3,894 |
| Diluted EPS | ₩6,914 | ₩4,438 | ₩1,966 | ₩3,437 | ₩3,888 |
| Revenue Per Share | ₩20,999 | ₩18,023 | ₩16,393 | ₩15,249 | ₩16,538 |
| Shares | |||||
| Basic Shares Outstanding | 233.2M | 231.0M | 217.0M | 142.7M | 138.1M |
| Diluted Shares Outstanding | 233.2M | 231.0M | 217.0M | 142.7M | 138.3M |
| Profitability Metrics | |||||
| EBITDA | 1931.7B | 1452.1B | 1069.9B | 937.8B | 801.9B |
| D&A | 291.4B | 287.5B | 418.2B | 245.8B | 175.3B |
| EBIT | 1640.3B | 1168.5B | 651.7B | 692.1B | 626.6B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026